Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. af Dowman, J, Tomlinson, J, Newsome, P

Pathogenesis of non-alcoholic fatty liver disease. af Dowman, J, Tomlinson, J, Newsome, P

The diagnosis of non-alcoholic fatty liver disease: authors' reply af Dowman, J, Tomlinson, J, Newsome, P

Current therapeutic strategies in non-alcoholic fatty liver disease. af Dowman, J, Armstrong, M, Tomlinson, J, Newsome, P

Orlistat for overweight subjects with nonalcoholic steatohepatitis. af Dowman, J, Stocken, D, Tomlinson, J, Newsome, P, Newsome, P

5-ALPHA-REDUCTASE-1 KNOCKOUT PROTECTS AGAINST HEPATOCARCINOGENESIS IN A MURINE MODEL OF NASH af Dowman, J, Hopkins, L, Armstrong, M, Gathercole, L, Lalor, P, Hubscher, S, Tomlinson, J, Newsome, P

Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. af Dowman, J, Hopkins, L, Reynolds, G, Nikolaou, N, Armstrong, M, Shaw, J, Houlihan, D, Lalor, P, Tomlinson, J, Hübscher, S, Newsome, P

Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. af Dowman, J, Hopkins, L, Reynolds, G, Armstrong, M, Nasiri, M, Nikolaou, N, van Houten, E, Visser, J, Morgan, SA, Lavery, G, Oprescu, A, Hübscher, S, Newsome, P, Tomlinson, J